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Pancreatic cancer is often associated with an intense production of interstitial collagens, known as the desmoplastic reaction. To
understand more about desmoplasia in pancreatic cancer, the expression of mRNA for type I and III collagens and potent desmoplastic
inducing growth factors transforming growth factor-b (TGF-b), connective tissue growth factor (CTGF), acidic and basic fibroblast
growth factor (FGF), platelet-derived growth factor (PDGF) A and C and epidermal growth factor (EGF) was analysed by quantitative
RT–PCR. Expression of both collagens in 23 frozen primary pancreatic cancer nodules was significantly higher than that in 15 non-
neoplastic pancreatic tissues. The expressions of mRNAs for TGF-b, acidic FGF, basic FGF and PDGF C were likewise higher in surgical
cancer nodules, while that of CTGF, PDGF A and EGF were not. Among these growth factors, the expression of TGF-b mRNA
showed the most significant correlation with that of collagens (Po0.0001). By immunohistochemistry, TGF-b showed faint cytoplasmic
staining in cancer cells. In contrast, isolated cells, mainly located on the invasive front surrounding cancerous nests, were prominently
and strongly stained. These TGF-b-positive cells contained a segmented nucleus, were negative for anti-macrophage (CD68) and
positive for anti-granulocyte antibodies, indicating their granulocytic nature. In conclusion, TGF-b seemed to play a major role among
the various growth factors in characteristic overproduction of collagens in pancreatic cancer. Moreover, the predominant cells that
express TGF-b were likely to be infiltrated granulocytes (mostly are neutrophils) and not pancreatic cancer cells.
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Pancreatic adenocarcinoma is a highly lethal disease with no
definitive therapy (Warshaw and Fernandez-del Castillo, 1992;
Neoptolemos et al, 2003). One hallmark of pancreatic adenocarci-
noma is the intense production of interstitial components, known
as the desmoplastic reaction (Iacobuzio-Donahue et al, 2002). As a
result, the proportion of pancreatic cancer cells is less than 20 –
40% of the tumour mass (Kloppel et al, 1985), while the remaining
60 – 80% includes interstitial cells (fibroblast, endocells and
inflammatory cells) and proliferated interstitial components
include collagens, followed by fibronectin, laminin and proteogly-
can (Gress et al, 1995; Imamura et al, 1995; Linder et al, 2001).
The desmoplastic reaction has been reported to be stimulated by
various growth factors including epidermal growth factor (EGF)
(Gospodarowicz, 1983), platelet-derived growth factor (PDGF)
(Gospodarowicz, 1983; Tahara, 1990), connective tissue growth
factor (CTGF) (Frazier et al, 1996), fibroblast growth factor (FGF)
(Gospodarowicz, 1983; Powers et al, 2000) and transforming
growth factor-b (TGF-b) (Roberts et al, 1986; Fine and Goldstein,
1987; Sappino et al, 1990; McCartney-Francis and Wahl, 1994). In
various malignancies including pancreatic cancer, overexpression
of these growth factors is frequently observed (Korc et al, 1992;
Friess et al, 1993; Yamanaka et al, 1993; Ebert et al, 1995; Gold,
1999; Wenger et al, 1999) and has been associated with a
significant decrease in the survival and advanced tumour stage
(Friess et al, 1993). Comprehensive analysis, however, concerning
the growth factors that have the strongest impact on the induction
of the desmoplastic reaction has never been reported; furthermore,
as to which one of the cellular component (i.e. neoplastic cells and
interstitial cells) contributing to the overexpression of growth
factors inducing desmoplasia in pancreatic cancer has remained
obscure. It is generally believed that the cancerous component
secretes the growth factors that give rise to this host reaction (Korc
et al, 1992; Friess et al, 1993; Yamanaka et al, 1993; Ebert et al,
1995; Gold, 1999; Wenger et al, 1999). However, as haematopoietic
cells including lymphocytes, macrophages and granulocytes are
also capable of secreting growth factors (Roberts and Sporn, 1988;
Grotendorst et al, 1989; Leonardi et al, 2000), we hypothesised that
infiltrated haematopoietic cells in addition to cancer cell itself
could be a source of growth factors that result in induction of
desmoplasia.
In order to better understand the molecular mechanism of
behind desmoplasia in pancreatic cancer, we have analysed the
expression of mRNA of collagens and potent desmoplastic
inducing growth factors. We demonstrate that expression of
collagens was significantly correlated with that of TGF-b in
primary pancreatic cancers, and, moreover, that the main source
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neutrophils) and not cancer cells.
MATERIAL AND METHODS
Surgical resected tissues of human pancreatic cancer
The pancreatic cancer tissues used in this study were obtained
from patients (10 male; 13 female) undergoing surgery for
pancreatic adenocarcinoma in the National Cancer Center Hospital
East Japan from 1999 to 2002. The median age was 66 years,
ranging from 52 to 81. There was one patient with stage I, two
patients with stage II, 10 patients with stage III and 10 patients
with stage IV disease. In all, 15 non-neoplastic pancreatic tissues
obtained from the same patients were also evaluated. Specimens
ranging from 100 to 300mg were immediately homogenised in
TRIZOL reagent solution (Life Technologies, Gaithersburg, MD,
USA) using multi-beads shocker (YASUI kikai, Osaka, Japan) after
surgical removal. Samples were stored at  801C until RNA was
extracted.
Cultured cell lines
Six human pancreatic cancer cell lines were analysed. ASPC-1,
BxPC-3, CAPAN-1 and MiaPaca-2 were obtained from the
American Type Culture Collection (ATCC) (Bethesda, MD, USA),
PSN-1 was from the Central Animal Laboratory National Cancer
Center Research Institute (Tokyo, Japan) and SUIT-2 cells were
generously provided by Dr Iwamura (Miyazaki Medical College,
Miyazaki, Japan). Two gastric cancer cell lines (KATO3 and
MKN45), two colon cancer cell lines (COLO201 and SW1116) and
two fibroblast (MRC-5 and WI-38) cell lines were also analysed
(ATCC). All cell lines were grown in either RPMI1640 or
Dulbecco’s modified Eagle medium (Sigma Aldrich, Taufkirchen,
Germany) containing 10% heat-inactivated foetal bovine serum
(Sigma). All cell lines were kept in a humidified atmosphere
containing 5% CO2 at 371C. Approximately 1 10
7 cells were
sheared in 1ml of TRIZOL reagent solution using a 21G needle.
The homogenate was kept at  801C until RNA was extracted.
RNA extraction
RNA from surgically resected tissues was extracted from about
100mg of homogenised tissue in TRIZOL reagent solution.
Samples were treated with 40U of RNase-free DNase I (TAKARA,
Shiga, Japan) in 200ml DEPC (diethylpyrocarbonate)-treated water,
10mM MgCl2 and 40U of RNase Inhibitor (TOYOBO, Osaka,
Japan) at room temperature for 15min.
Reverse transcription (RT)
All cDNAs were synthesised from 10mg total RNA using 50mM
oligo (dT)20 primer in a total volume of 50ml using ThermoScriptt
RT–PCR System (Life Technologies) according to the manufac-
turer’s protocol. cDNAs were purified using the QIA quick PCR
purification Kit (QIAGEN, Hilden, Germany) and eluted in 100ml
of 10mM Tris–HCl (pH 8.5).
Real-time quantitative RT – polymerase chain reaction (RT
– PCR)
Expression of type I collagen and type III collagen mRNAs was
analysed since they are major proteins of the stromal component.
Transforming growth factor-b, CTGF, acidic FGF (aFGF), basic
FGF (bFGF), PDGF A, PDGF C and EGF were analysed as they are
potent desmoplastic inducing molecules. Polymerase chain reac-
tion primer pairs for mRNA quantification, intending to flank at
least one intron, were designed based on coding sequences
obtained from the GenBank Sequence Database (http://
www.ncbi.nlm.nih.gov/Genbank/index.html) (Table 1).
Quantitative real-time RT–PCR
Quantitative real-time PCR was carried out using a LightCyclert
instrument (Roche, Mannheim, Germany) using SYBR green. In
all, 1ml of cDNA solution corresponding to 100ng of total RNA
was subjected to 40 PCR cycles of 10s at 951C, 10s at 53 – 651C and
5 – 15s at 721Ci na1 0ml mixture containing 1ml LightCycler-DNA
Master SYBR Green I (Roche), 2.25 – 5mM MgCl2 and 0.25mM each
of forward and reverse gene-specific primers. Polymerase chain
reaction conditions and detection temperature of fluorescent
products were optimised for each gene by meticulous pilot studies
(Table 2). Amplification specificities of the PCR products were
confirmed by melting curve analysis of the LightCycler instru-
ments, and re-confirmed by agarose gel electrophoresis.
An external standard curve for each gene was generated using
serial 10
2-fold dilutions of RT–PCR products, corresponding to
1 10
8 –1 10
2 copiesml
 1, to estimate the gene-specific mRNA
copy number per 100ng total RNA of each sample.
Immunohistochemistry
The expression of TGF-b was investigated by immunohistochem-
istry (IHC) using anti-human TGF-b1 antibody in 23 pancreatic
cancer tissues. Potent TGF-b-producing haematopoietic cells, that
is, macrophages or granulocytes, were also visualised by IHC.
Paraffin-embedded, formalin-fixed sections were subjected to
antigen retrieval by immersion in 0.1 M citrate buffer (pH 6.0)
and microwaving at 951C or by incubation with protease K
(DAKO, Glostrup, Denmark) at room temperature for 10min.
Endogenous peroxidase was inactivated by incubating in 0.3%
H2O2 in methanol for 10 – 20min. Nonspecific binding was
blocked by treatment with 5% skim milk and 2% bovine serum
albumin in PBS for 30min. Tissues were then incubated with
polyclonal rabbit antibodies against anti-human TGF-b1 (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), as well as
Table 1 PCR primers for collagens and potent desmoplastic inducing growth factors
Gene Accession no. Position
Product
length (bp) Forward primer sequence Reverse primer sequence
Type I collagen NM_000088 4010–4390 381 50-CAG TTC GAG TAT GGC GGC G-30 50-GAC AGG GCC AAC GTC GAA G-30
Type III collagen NM_000090 3632–3936 305 50-AAA AAG CTG GCG GTT TTG CC-30 50-CCG TGG AAC ATT CAA AGG AT-30
TGF-b X02812 402–651 250 50-CTT CAA CAC ATC AGA GCT CCG A-30 50-GCC CTC AAT TTC CCC TCC AC-30
CTGF M92934 503–871 369 50-AGC CCA AGG ACC AAA CCG TG-30 50-GGC CGT CGG TAC ATA CTC CA-30
aFGF X65778 318–468 150 50-GAA CCA TTA CAA CAC CTA TAT-30 50-TTA ATC AGA AGA GAC TGG C-30
bFGF M27968 254–445 192 50-TGA AGG AAG ATG GAA GAT TA-30 50-GAA AAA GTA TAG CTT TCT GC -30
PDGF A A09204 266–538 273 50-AGG AAG CTG TCC CCG CTG TC-30 50-CGC AGG CGC ACT CCA AAT GC-30
PDGF C AF260738 493–739 247 50-CCA CAA TTC ACA GAA GCT GT-30 50-ATC TTA CCT CCT CTG TTA GAA GG-30
EGF NM_001963 3246–3586 341 50-GCC TGC TGA CAC TGA GGA T-30 50-CCC TTT GTT GCC ATA ATG GG-30
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and anti-human granulocyte (Medical & Biological Laboratories
Co., Nagoya, Japan) at a dilution of 1:100 in a humidified
chamber at 41C overnight. Primary antibody reactions of
TGF-b and granulocyte were enhanced using the Envisionþkit
(DAKO). CD68 antibody treatment was followed by incubation
with rabbit anti-mouse secondary antibody and enhanced using
Strept AB Complex/HRP kit (DAKO). The immunoreaction was
visualised with 0.05% 3,30-diaminobenzidine (DAB) solution for 1
– 10min at room temperature. After washing in distilled water, the
specimens were counterstained with haematoxylin, dehydrated
and mounted.
As negative control for TGF-b1 analysis, the primary antibody
was substituted for by anti-green fluorescence protein (GFP) rabbit
polyclonal antibodies (Molecular Probes, Inc., Eugene, OR, USA)
and processed as described above. As a negative control for
granulocyte and macrophage visualisation, anti-mouse H2Kb
mouse monoclonal antibodies (PharMingen, San Diego, CA,
USA) were used.
Double immunofluorescence stain
In order to corroborate the precise localisation of TGF-b, five
representative pancreatic cancer tissues were subjected to double
immunofluorescence staining. Sections were incubated with the
primary antibody pairs against (TGF-bþCD68) or (TGF-
bþgranulocyte) for 1h at room temperature in a humidified
chamber. Transforming growth factor-b was labelled red with
Alexa Fluor 546 F(ab0)2 fragments of goat anti-rabbit IgG
(Molecular Probes, Inc., OR, USA) at a dilution of 1:1000,
and CD68 and granulocytes were labelled green with fluorescein
(FITC) horse anti-mouse IgG (Vector Laboratories, Inc., CA, USA)
at a dilution of 1:100 by incubation for 30min at
room temperature. The sections were mounted in PermaFliort
Aqueous Mounting Medium (ThermoShandon, PA, USA) and
examined with a MRC-1024 confocal imaging system (BIO-RAD,
Herts, UK).
Statistical analysis
As the expression of mRNAs for type I collagen, type III collagen,
TGF-b, CTGF, aFGF, bFGF, PDGF A, PDGF C and EGF exhibited
asymmetrical distributions, nonparametric tests (Wilcoxon paired
tests) were used. The relationship between expression of collagens
and TGF-b, CTGF, aFGF, bFGF, PDGF A, PDGF C and EGF was
assessed by linear regression analysis (Mann–Whitney U test).
Significance was defined as Po0.05. Statistical calculations were
performed with the Stat View software package (Version 5.0:
Abacus Concepts, Inc., Berkeley, CA, USA).
RESULTS
Expression of mRNAs for collagens and growth factors in
surgical specimens
mRNA copy numbers are listed in Table 3 and represented in
Figure 1. In surgically resected pancreatic cancerous lesions (¼C),
the expression of mRNA for type I collagen and type III collagen
was significantly higher (2.9- and 2.4-fold, respectively) compared
to non-neoplastic pancreatic tissues (¼N) (Table 3, Figure 1A).
The expression of mRNA for TGF-b in C was also higher (3.4-fold)
than that in N (Figure 1B). The expression of mRNA for aFGF (3.7-
fold), bFGF (2.6-fold), PDGF C (2.8-fold) and CTGF (2.2-fold) was
also higher in cancer tissue, while that for PDGF A ( 1.1-fold) and
EGF ( 2.5-fold) was lower (Figure 1B). All growth factors with
upregulated expression correlated with type I and type III collagen
gene expression. (Type I collagen: TGF-b (r¼0.684, P¼0.0003),
CTGF (r¼0.436, P¼0.0376), aFGF (r¼0.245, P¼0.2591), bFGF
(r¼0.119, P¼0.3206), PDGF C (r¼0.562, P¼0.0052), Type III
collagen: TGF-b (r¼0.727, Po0.0001), CTGF (r¼0.624,
P¼0.0015), aFGF (r¼0.482, P¼0.02), bFGF (r¼0.164,
P¼0.4547), PDGF C (r¼0.562, P¼0.0007)). These results
indicated that the expression of TGF-b showed high correlation
with the expression of type I collagen (Figure 2A) and type III
collagen (Figure 2B).
Type I and type III collagen and TGF-b mRNA expression
in cell lines
The copy numbers of the collagens and TGF-b mRNA per 100ng
total RNA were analysed for various cell lines. The expression of
mRNA for the collagens in fibroblast cell lines was prominent, while
the pancreatic cancer cell lines were nearly negative for expression
Table 2 PCR conditions
Gene
MgCl2
(mM)
Annealing
temp. (8C)
Elongation
time (s)
Detect
temp. (8C)
a
Type I collagen 2.25 63 15 88
Type III collagen 4 63 10 80
TGF-b 36 5 88 6
CTGF 2.25 66 13 85
aFGF 4 53 5 81
bFGF 5 58 7 72
PDGF A 3 68 10 88
PDGF C 3 56 9 79
EGF 4 65 13 72
aTemperature for detection of fluorescent PCR products.
Table 3 Expression of collagens and potent desmoplastic inducing
growth factors
Gene
Copy number 10
2 copies/
100ng total RNA P-value
Type I collagen C 2497.173322.7 0.018
N 864.671087.4
Type III collagen C 2103.172305.7 0.018
N 876.071143.8
TGF-b C 12.9715.2 0.026
N 3.873.9
aFGF C 4.175.4 0.002
N 1.172.5
bFGF C 4.676.5 0.034
N 1.872.2
PDGF C C 14.9723.7 0.028
N 5.3711.0
CTGF C 212.87380.3 0.170
N 96.97159.7
PDGF A C 3.473.1 0.347
N 3.975.3
EGF C 1.373.1 0.179
N 3.175.1
C¼cancerous lesions, N¼noncancerous lesions.
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collagen production, rather than pancreatic cancer cells. Expression
of TGF-b is not a specific characteristic of pancreatic cancer cell
lines and, in fact, cell lines originating from fibroblasts, gastric
cancer and colon cancers also express TGF-b mRNA at the same or
higher levels as the pancreatic cancer cell lines (Figure 3B).
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Figure 1 Expressed copy number per 100ng of total RNA in pancreatic cancerous (C) and noncancerous (N) lesions from surgical specimens as
measured by real-time RT–PCR. (A) Expressions of type I collagen and type III collagen in C were significantly higher than that of N. (B) Expressions of
TGF-b, aFGF, bFGF and PDGF C in C were significantly higher than that of N, while those of CTGF, PDGF A and EGF were not significant. Bars indicate
mean values. NS: not significant.
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Since the expression of TGF-b mRNA showed a prominent
correlation with the expression of collagen mRNA, the protein
distribution of TGF-b in pancreatic cancer tissues was examined
using immunohistochemistry. Immunohistochemistry with TGF-b
(Figure 4) demonstrated that the staining in pancreatic cancer cells
was extremely faint positive at short DAB reaction times (E1min)
(arrows in Figures 4A and B), and was barely recognisable after
longer incubation (E10min) (arrows in Figures 4C and D). In
contrast, highly prominent immunostaining was observed in
isolated cells bordering the cancer nests even at short DAB
reaction times (arrow heads in Figures 4A and B). These TGF-b-
positive cells were predominantly distributed at the invasive front
area (or tumour periphery) (Figures 4A and C), but were rare in
the tumour core (Figures 4B and D). High-power field observation
of these cells revealed that they possessed bandform and/or
segmented nuclei and were presumed to be haematopoietic
granulocytes (Figures 4A and C). Immunohistochemistry with
anti-GFP rabbit polyclonal antibodies demonstrated complete
negative staining for these isolated cells (Figures 4E and F),
demonstrating that immunostaining with anti-TGF-b was not an
artefact but a result of true immuno-reaction between antigens.
The other stromal components such as fibroblasts and endothelial
cells showed only weak or no immunostaining (Figure 4).
CD68þ macrophages and antigranulocyte antibody-positive
granulocyte cells were also distributed in the area surrounding the
cancer nests, similar to the distribution of TGF-b-positive cells
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Figure 3 Expression of collagens and TGF-b mRNA in various cancer
cell lines. (A) Expressions of type I and type III collagens were negative in
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compared with fibroblasts. (B) Since the expression of TGF-b in pancreatic
cancer cell lines was the same or less than that in fibroblasts, gastric cancer
and colon cancer cell lines, it was presumed that TGF-b overexpression is
not a specific feature for pancreatic cancer cells.
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macrophages had a single nucleus, while the antigranulocyte
antibody-positive granulocyte cells harboured segmented nuclei.
Thus, the cells that overexpress TGF-b can be confidently
identified as granulocytes. Moreover, in gastric and colon cancer
tissues, isolated cells with segmented nuclei around cancer nests at
the invasive front also showed strong staining for TGF-b (Figure 6).
Double immunofluorescence stain, (TGF-bþCD68) or
(TGF-bþgranulocyte)
In order to unambiguously identify the cells producing TGF-b in
pancreatic cancer tissues, double immunofluorescence staining
was carried out. Distribution of TGF-b-positive cells did not
correlate with the distribution of CD68þ cells (Figures 7A–C).
However, double staining with anti-TGF-b and antigranulocyte
antibodies showed clearly concordant results (Figures 7D–F).
These results indicated that the major cellular source of TGF-b in
pancreatic tumour tissues, in addition to cancer cells, is
granulocytes and not macrophages.
Subtype of granulocytes by morphological observation
In order to identify the subclass of TGF-b-producing granulocytes,
careful microscopical observation for haematoxylin–eosin-stain-
ing sections was performed. Majorities of the granulocytes were
presumed to be neutrophils. As shown in representative pictures in
Figures 8A and B, these cells contain polymorphonucleus with
cytoplasms stained pink, indicating their neutrophilic feature.
Eosinophils, characterised by its distinctive cytoplasmic granules
stained red (arrows in Figures 8C and D), were also noted,
however, the population of this subtype should at most be 3 – 5%
of entire granulocytes.
DISCUSSION
Comprehensive mRNA analysis of several growth factors in
pancreatic cancer, including TGF-b, CTGF, aFGF, bFGF, PDGF
A, PDGF C and EGF, resulted in the finding that TGF-b is likely to
be a potent inducer of the desmoplastic reaction. Furthermore,
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Figure 4 TGF-b immunohistochemistry in pancreatic adenocarcinoma. Transforming growth factor-b immunostaining was visualised by short (E1min)
and long (E10min) reactions with DAB. Note that staining for cancer cells is barely visible at short DAB staining times (closed arrows) in both the tumour
periphery (A) and core (B), and only slightly apparent after a 10-min reaction (closed arrows) in both the tumour periphery (C) and core (D). Intense TGF-
b immunoreactivity was found in granular cells adjacent to the pancreatic cancer nests, even at short DAB incubation periods (open arrow heads) (A, B).
These TGF-b-positive cells were predominantly observed at the tumour periphery (A), and are rare in the tumour core (B). Immunohistochemistry using
anti-GFP rabbit polyclonal antibodies as a negative control against anti-TGF-b rabbit polyclonal antibody resulted in negative staining in both the tumour
periphery (E) and core (F). NC: negative control.
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as a predominant source of TGF-b.
In this study, we initially demonstrated that the expression of
type I and type III collagens in pancreatic cancer tissues was at
least three-fold higher than that in normal pancreatic tissue
(Figure 1A), confirming previous reports (Gress et al, 1995;
Imamura et al, 1995; Linder et al, 2001). The origin of type I and
type III collagens mRNA has been assumed to be cancer stroma
(Gress et al, 1995), a finding supported by our studies in pancreatic
cancer cell lines. Indeed, cancer cells are capable of synthesis and
production of extracellular matrix proteins (Niitsu et al, 1988;
Yoshida et al, 1989; Lohr et al, 1994), although the expression of
collagen mRNAs in the pancreatic cancer cell lines was somewhat
lower in comparison to that of fibroblast cell lines (Figure 3A).
Furthermore, the expression of collagens from pancreatic cancer
cells does not increase in vivo, that is, subcutaneous xenotrans-
plantation in immunodeficient mice (unpublished data).
In order to better understand the molecular mechanisms
underlying the stromal reaction, we examined the levels of several
growth factors capable of inducing desmoplasia. Though plural
molecules including TGF-b, aFGF, bFGF and PDGF C were
overexpressed in pancreatic cancer (Figure 1B) and presumed to
be associated with desmoplasia, we focused on TGF-b since its
expression showed the most significant correlation with that of
collagens. The expression of TGF-b in pancreatic cancer tissue was
actually 3.5-fold higher than that found in normal pancreatic
regions (Figure 1B). These results correlate with that of Friess et al
(1993), who previously reported similar semiquantitative results by
Northern blot analysis and/or in situ hybridisation. Other authors
have reported on the overexpression of TGF-b in various cancer
CD
B A
Low power High power
CD68
Antigranulocyte
TGF- 
E F
Figure 5 Distribution of TGF-b, CD68 and antigranulocyte-positive cells in pancreatic adenocarcinoma. The distribution of isolated TGF-b-positive cells in
pancreatic cancer (A) was similar to that of macrophage (i.e. CD68þ cells) (C) and granulocytes (E) in low power field observation. However, in high
power field observation, the morphology of TGF-b1-positive isolated cells (B) coincided with antigranulocyte-positive segmented nucleus cells (F) but not
CD68þ mononuclear cells (D).
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situ hybridisation (Samuels et al, 1989; Yoshida et al, 1989; Barrett-
Lee et al, 1990; Gorsch et al, 1992; Walker and Dearing, 1992;
Mahara et al, 1994), although none of these methods were
quantitative. Our results extend these earlier studies by providing
independent, quantitative analysis of the overexpression of TGF-b
in pancreatic cancer by employing real-time RT–PCR methods.
While the expressions of both TGF-b and collagens have been
examined independently, their expressions relative to one another
have not been considered. The utilisation of quantitative RT–PCR
method enabled us to evaluate the correlation between the
expressions of TGF-b mRNA and collagens. Both in vitro and in
vivo experimental evidence has been accumulating, showing that
TGF-b stimulates the production of collagens from fibroblasts. In
fact, cultured fibroblasts increased the production of collagen from
three- to five-fold when incubated with appropriate concentrations
of TGF-b (Raghow et al, 1987; Varga et al, 1987). When TGF-b was
directly injected into the subcutaneous tissue of newborn mice,
accelerated fibrosis, that is, activation of fibroblasts to produce
collagens, was demonstrated (Roberts et al, 1986; Shinozaki et al,
1997). In clinical diseases including pulmonary fibrosis and
chronic renal allograft damage, TGF-b is also considered to be a
main pathogenic factor for the overproduction of collagen
(Nicholson et al, 1999). Obviously, TGF-b is not the only factor
that can stimulate collagen expression in fibroblasts, since insulin
and/or growth factors analysed here also regulate the production
of type I collagen (Krupsky et al, 1996). Nonetheless, it can be
stated here that TGF-b may be one of the main inducers of the
desmoplastic reaction in pancreatic cancer.
One question concerns the cellular origin of TGF-b in pancreatic
cancer nodules. Previous reports have indicated that the
upregulated TGF-b originated from cancer cells, since
Pancreatic cancer
Gastric cancer
Colon cancer
Low power High power
A B
CD
EF
Figure 6 TGF-b immunoreactivity in pancreatic, gastric, and colon cancer tissues. TGF-b immunoreactivity was found in isolated cells around cancer nests
in pancreatic cancer tissue (A) and many of these cells harboured segmented nuclei (B). Transforming growth factor-b-positive segmented nuclei cells were
likewise observed in gastric (C, D) and colon (E, F) cancers, especially in the tumour periphery. Low power field (A, C, E). High power field (B, D, F).
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strated that the TGF-bs were localised in tumour cytoplasm (Friess
et al, 1993; Coppola et al, 1998). However, it must be considered
that the proportion of cancer cells in pancreatic cancer nodules is
rather low (20 – 30% at the highest) as a result of desmoplastic
reaction (Kloppel et al, 1985). If indeed these cancer cells were the
origin of overexpressed TGF-b in pancreatic cancer nodules, each
cancer cell would be expected to show prominent TGF-b staining.
However, our immunohistochemical study for TGF-b demon-
strated only faint cytoplasmic staining in cancer cells even after a
10-min reaction with DAB (Figure 4D). In contrast, isolated cells in
the surrounding stroma of the cancer nests showed prominent
positive staining even after short (1min) DAB reaction times
(Figure 4A). Initially, we assumed that this staining might be due
to artefactual staining by endogenous peroxidase. However,
staining without incubation of primary antibodies resulted in
negative staining for these cells. A second possibility for false-
positive staining could also be nonspecific binding of the Fc
fragment or trapping of antibody in these isolated cells. In order to
rule out this possibility, we carried out incubation with the first
antibody with the same type of antibody against an antigen that is
not expressed in human tissues, that is, polyclonal rabbit antibody
against anti-GFP. Again, this negative control resulted in no
staining in these isolated cells (Figures 4E and F). We are therefore
confident that the isolated cells in stroma surrounding the cancer
nest are actually strongly positive for TGF-b.
It then remained to determine the identity of the cells that
overexpress TGF-b. We initially postulated that these cells were
macrophages, since it has been reported that macrophages can
secrete TGF-b (Assoian et al, 1987; Appleton et al, 1993) and,
moreover, that the expression of TGF-b is associated with
fibroblast collagen synthesis (Khalil et al, 1989). However, while
the distribution of TGF-b-positive cells and CD68þ cells was
somewhat similar, double-staining IHC did not show consistent
double staining with these two antibodies (Figure 6). We then
focused on granulocytes, since these cells, including neutrophils
and eosinophils, have also been reported to express TGF-b
(Grotendorst et al, 1989; Wong et al, 1991). Moreover, in the
acute phase of disease, neutrophil granulocytes have been shown
to express higher amounts of TGF-b mRNA with respect to
lymphocytes and monocytes/macrophages (Ossege et al, 1996).
Furthermore, the TGF-b produced by eosinophils has been shown
to be involved in connective tissue remodelling and collagen
synthesis (Stahle-Backdahl et al, 2000; Nomura et al, 2002). As
shown in Figure 7, these TGF-b-positive cells coincided extremely
well with that of antigranulocyte antibody-positive cells, and
morphological evidence supported a notion that majorities of these
cells were neutrophils (Figure 8). Together with previous reports
that TGF-b is distributed in stromal inflammatory cells including
granulocytes as well as cancer cells (Roberts et al, 1986; Assoian
et al, 1987), it seems reasonable to regard that the predominant
source of high levels of TGF-b may be infiltrating neutrophil,
though bulk tumoral TGF-b should be accumulation of that from
neutrophils, eosinophils and cancer cells. A precise and conclusive
cellular source of TGF-b in a tumoral context, however, remains to
be identified through in situ hybridisation.
Neutrophil infiltration is a biological phenomenon that is
usually associated with acute inflammation such as bacterial
infection. The present pancreatic cancer population was basically
free from sign of acute pancreatitis showing high serum amylase
level at the time of operation. Furthermore, resected specimens
demonstrated no sign of infection such as the presence of pus. We
believe that this neutrophil infiltration observed in the present
study may be an important phenomenon that should be focused in
understanding pancreatic cancer progression. Observation of only
the central core of the pancreatic cancer may have missed this
neutrophil infiltration, as we demonstrated in Figure 4. In order to
evaluate whether infiltration of granulocytes overexpressing TGF-b
is specific to pancreatic cancer, we performed immunostaining for
TGF-b on gastric and colon cancer samples. As shown in Figure 6,
TGF-b-positive granulocytes are clearly present, especially at the
invasive front. Thus, TGF-b-secreting infiltrating granulocytes are
present in pancreatic, gastric and colon cancer; however, a
prominent desmoplastic reaction is observed only in the former.
This apparent discrepancy may be explained by the mechanism
of activation of TGF-b. Transforming growth factor-b is
generally released from cells in a latent, biologically inactive form
(Miyazono et al, 1993). Following release, it is activated by a
variety of mechanisms, including exposure to proteolytic enzymes
or alkaline pH conditions (Gleizes et al, 1997; Khalil, 1999). The
presence of proteases in the pancreas and the alkaline pH of
pancreatic juice may result in ideal conditions for activation of
latent TGF-b.
In conclusion, we demonstrated that TGF-b is overexpressed in
pancreatic cancer nodules and, moreover, that TGF-b is secreted
mainly by infiltrating granulocytes (mostly are neutrophils) and
not cancer cells. Once secreted, TGF-b can be activated in the
unique pancreatic environment, thereby stimulating fibroblasts to
D A
B
CD68
E
AG
CF
TGF-    + CD68
TGF-  TGF- 
TGF-  + AG
Figure 7 Confocal immunofluorescence images showing TGF-b (red)
(A, D), CD68 as a marker of macrophages (green) (B) and granulocytes
(green) (E). Transforming growth factor-b staining was topographically
different from the staining of CD68þ cells (C). However, double staining
with anti-TGF-b and antigranulocyte antibodies resulted in a consistent
overlap (F). AG: antigranulocyte.
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reaction in pancreatic cancer, a greater understanding and control
of the phenomenon of granulocyte infiltration, and control of
subsequent activation mechanisms of TGF-b, is urgently required.
Furthermore, the meaning of neutrophils infiltration in pancreatic
cancer progression, that is, whether it is associated with better or
worse prognosis, remains to be elucidated.
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